Outcomes of a standardized triple-drug regimen for the treatment of nontuberculous mycobacterial pulmonary infection

Clin Infect Dis. 2008 Jul 15;47(2):222-4. doi: 10.1086/589250.

Abstract

The treatment of fibrocavitatory pulmonary infection due to Mycobacterium avium complex and Mycobacterium malmoense poses a challenge. This study assessed microbial, inflammatory, radiographic, and clinical outcomes for a standardized 24-month triple-drug regime. Following treatment completion, all patients had fewer symptoms, experienced a reduction in systemic inflammation, and had negative sputum mycobacterial culture results.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Anti-Bacterial Agents / administration & dosage*
  • Blood Sedimentation
  • Ciprofloxacin / administration & dosage
  • Clarithromycin / administration & dosage*
  • Drug Resistance, Bacterial
  • Drug Therapy, Combination
  • Ethambutol / administration & dosage*
  • Female
  • Humans
  • Lung / diagnostic imaging
  • Lung / microbiology
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Mycobacterium Infections, Nontuberculous / diagnosis
  • Mycobacterium Infections, Nontuberculous / drug therapy*
  • Mycobacterium Infections, Nontuberculous / microbiology
  • Mycobacterium avium / drug effects
  • Mycobacterium avium / isolation & purification
  • Mycobacterium avium-intracellulare Infection / diagnosis
  • Mycobacterium avium-intracellulare Infection / drug therapy*
  • Nontuberculous Mycobacteria / drug effects
  • Nontuberculous Mycobacteria / isolation & purification
  • Radiography
  • Rifampin / administration & dosage*
  • Sputum / microbiology
  • Treatment Outcome
  • Tuberculosis, Pulmonary / diagnosis
  • Tuberculosis, Pulmonary / drug therapy*
  • Tuberculosis, Pulmonary / microbiology

Substances

  • Anti-Bacterial Agents
  • Ciprofloxacin
  • Ethambutol
  • Clarithromycin
  • Rifampin